#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

Just a few months af­ter mak­ing a splash at the Eu­ro­pean Hema­tol­ogy As­so­ci­a­tion sci­en­tif­ic con­fab with an ear­ly snap­shot of pos­i­tive da­ta for their BTK in­hibitor ARQ 531, Ar­Qule has won a $2.7 bil­lion buy­out deal from Mer­ck.

Mer­ck is scoop­ing up a next-gen BTK drug — which is mak­ing a splash at ASH to­day — from Ar­Qule in an M&A pact set at $20 a share $AR­QL. That’s more than twice Fri­day’s $9.66 close. And Mer­ck R&D chief Roger Perl­mut­ter her­ald­ed a deal that nets “mul­ti­ple clin­i­cal-stage oral ki­nase in­hibitors.”

This is the sec­ond biotech buy­out pact to­day, mark­ing a brisk tem­po of M&A deals in the lead-up to the big JP Mor­gan gath­er­ing in mid-Jan­u­ary. It’s no sur­prise the ac­qui­si­tions are both for can­cer drugs, where Sanofi will try to make its mark while Mer­ck beefs up a stel­lar on­col­o­gy fran­chise. And bolt-ons are all the rage at the ma­jor phar­ma play­ers, which you could al­so see in No­var­tis’ re­cent $9.7 bil­lion Med­Co buy­out.

Ar­Qule — which comes out on top af­ter their orig­i­nal lead drug foundered in Phase III — high­light­ed ear­ly da­ta on ‘531 at EHA from a group of 6 chron­ic lym­pho­cyt­ic leukemia pa­tients who got the 65 mg dose. Four of them ex­pe­ri­enced a par­tial re­sponse — a big ad­vance for a com­pa­ny that failed with ear­li­er at­tempts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER